A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).

NCT Number	NCT07423546
Lead Sponsor	New York State Psychiatric Institute Collaborators: Bristol-Myers Squibb
Conditions	SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Enrollment	12 participants
Start Date	2026-07-01
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-14